File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bcp.2010.02.012
- Scopus: eid_2-s2.0-77951298866
- PMID: 20219441
- WOS: WOS:000276986000008
- Find via
Supplementary
-
Bookmarks:
- CiteULike: 1
- Citations:
- Appears in Collections:
Article: An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation
Title | An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation | ||||
---|---|---|---|---|---|
Authors | |||||
Keywords | Antitumor mechanism ECyd NADPH NPC TIGAR | ||||
Issue Date | 2010 | ||||
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/biochempharm | ||||
Citation | Biochemical Pharmacology, 2010, v. 79 n. 12, p. 1772-1780 How to Cite? | ||||
Abstract | 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd) is a ribose-modified nucleoside analog of cytidine with potent anticancer activity in several cancers. The main antitumor mechanism of this promising RNA-directed nucleoside anti-metabolite is efficient blockade of RNA synthesis in cancer cells. Here, we examined the therapeutic potential of this RNA-directed anti-metabolite in in vitro models of nasopharyngeal cancer (NPC). In a panel of 6 NPC cell lines, ECyd effectively inhibited cellular proliferation at nM concentrations (IC 50:∼13-44nM). Moreover, cisplatin-resistant NPC cells were highly sensitive to ECyd (at nM concentration). The ECyd-mediated growth inhibition was associated with G 2/M cell cycle arrest, PARP cleavage (a hallmark of apoptosis) and Bcl-2 downregulation, indicating induction of apoptosis by ECyd in NPC cells. Unexpectedly, ECyd-induced significant downregulation of TIGAR, a newly described dual regulator of apoptosis and glycolysis. More importantly, this novel action of ECyd on TIGAR was accompanied by marked depletion of NADPH, the major reducing power critically required for cell proliferation and survival. We hypothesized that ECyd-induced TIGAR downregulation was crucially involved in the antitumor activity of ECyd. Indeed, overexpression of TIGAR was able to rescue NPC cells from ECyd-induced growth inhibition, demonstrating a novel mechanistic action of ECyd on TIGAR. We demonstrated for the first time that an RNA-directed nucleoside analog, ECyd, exerts its antitumor activity via downregulation of a novel regulator of apoptosis, TIGAR. Moreover, ECyd may represent a novel therapy for NPC. © 2010 Elsevier Inc. | ||||
Persistent Identifier | http://hdl.handle.net/10722/124469 | ||||
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.365 | ||||
ISI Accession Number ID |
Funding Information: VWYL has received research support. from Taiho Pharmaceutical Co., Ltd. in this study. ATCC had received an honorarium as the advisory board member in Taiho Pharmaceutical Co., Ltd. in 2008 and has received research support from Taiho Pharmaceutical Co., Ltd. independent of this study. Result of this study was presented in parts as a poster at the AACR Annual Meeting in Denver, USA, 2009. | ||||
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lui, VWY | en_HK |
dc.contributor.author | Lau, CPY | en_HK |
dc.contributor.author | Cheung, CSF | en_HK |
dc.contributor.author | Ho, K | en_HK |
dc.contributor.author | Ng, MHL | en_HK |
dc.contributor.author | Cheng, SH | en_HK |
dc.contributor.author | Hong, B | en_HK |
dc.contributor.author | Tsao, SW | en_HK |
dc.contributor.author | Tsang, CM | en_HK |
dc.contributor.author | Lei, KIK | en_HK |
dc.contributor.author | Yamasaki, Y | en_HK |
dc.contributor.author | Mita, A | en_HK |
dc.contributor.author | Chan, ATC | en_HK |
dc.date.accessioned | 2010-10-31T10:36:09Z | - |
dc.date.available | 2010-10-31T10:36:09Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | Biochemical Pharmacology, 2010, v. 79 n. 12, p. 1772-1780 | en_HK |
dc.identifier.issn | 0006-2952 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/124469 | - |
dc.description.abstract | 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd) is a ribose-modified nucleoside analog of cytidine with potent anticancer activity in several cancers. The main antitumor mechanism of this promising RNA-directed nucleoside anti-metabolite is efficient blockade of RNA synthesis in cancer cells. Here, we examined the therapeutic potential of this RNA-directed anti-metabolite in in vitro models of nasopharyngeal cancer (NPC). In a panel of 6 NPC cell lines, ECyd effectively inhibited cellular proliferation at nM concentrations (IC 50:∼13-44nM). Moreover, cisplatin-resistant NPC cells were highly sensitive to ECyd (at nM concentration). The ECyd-mediated growth inhibition was associated with G 2/M cell cycle arrest, PARP cleavage (a hallmark of apoptosis) and Bcl-2 downregulation, indicating induction of apoptosis by ECyd in NPC cells. Unexpectedly, ECyd-induced significant downregulation of TIGAR, a newly described dual regulator of apoptosis and glycolysis. More importantly, this novel action of ECyd on TIGAR was accompanied by marked depletion of NADPH, the major reducing power critically required for cell proliferation and survival. We hypothesized that ECyd-induced TIGAR downregulation was crucially involved in the antitumor activity of ECyd. Indeed, overexpression of TIGAR was able to rescue NPC cells from ECyd-induced growth inhibition, demonstrating a novel mechanistic action of ECyd on TIGAR. We demonstrated for the first time that an RNA-directed nucleoside analog, ECyd, exerts its antitumor activity via downregulation of a novel regulator of apoptosis, TIGAR. Moreover, ECyd may represent a novel therapy for NPC. © 2010 Elsevier Inc. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/biochempharm | en_HK |
dc.relation.ispartof | Biochemical Pharmacology | en_HK |
dc.subject | Antitumor mechanism | en_HK |
dc.subject | ECyd | en_HK |
dc.subject | NADPH | en_HK |
dc.subject | NPC | en_HK |
dc.subject | TIGAR | en_HK |
dc.subject.mesh | Apoptosis - drug effects | - |
dc.subject.mesh | Cytidine - analogs and derivatives - pharmacology | - |
dc.subject.mesh | Down-Regulation | - |
dc.subject.mesh | Intracellular Signaling Peptides and Proteins - genetics - metabolism | - |
dc.subject.mesh | Nasopharyngeal Neoplasms - drug therapy - pathology | - |
dc.title | An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0006-2952&volume=79&issue=12&spage=1772&epage=1780&date=2010&atitle=An+RNA-directed+nucleoside+anti-metabolite,+1-(3-C-ethynyl-beta-D-ribopentofuranosyl)+cytosine+(ECyd),+elicits+antitumor+effect+via+TP53-induced Glycolysis+and+Apoptosis+Regulator+(TIGAR)+downregulation | en_HK |
dc.identifier.email | Tsao, SW:gswtsao@hkucc.hku.hk | en_HK |
dc.identifier.authority | Tsao, SW=rp00399 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.bcp.2010.02.012 | en_HK |
dc.identifier.pmid | 20219441 | - |
dc.identifier.scopus | eid_2-s2.0-77951298866 | en_HK |
dc.identifier.hkuros | 182818 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-77951298866&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 79 | en_HK |
dc.identifier.issue | 12 | en_HK |
dc.identifier.spage | 1772 | en_HK |
dc.identifier.epage | 1780 | en_HK |
dc.identifier.isi | WOS:000276986000008 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Lui, VWY=7004231347 | en_HK |
dc.identifier.scopusauthorid | Lau, CPY=36608195100 | en_HK |
dc.identifier.scopusauthorid | Cheung, CSF=35080091300 | en_HK |
dc.identifier.scopusauthorid | Ho, K=34971221500 | en_HK |
dc.identifier.scopusauthorid | Ng, MHL=35292609300 | en_HK |
dc.identifier.scopusauthorid | Cheng, SH=7404681588 | en_HK |
dc.identifier.scopusauthorid | Hong, B=7202125896 | en_HK |
dc.identifier.scopusauthorid | Tsao, SW=7102813116 | en_HK |
dc.identifier.scopusauthorid | Tsang, CM=24831236400 | en_HK |
dc.identifier.scopusauthorid | Lei, KIK=7102208067 | en_HK |
dc.identifier.scopusauthorid | Yamasaki, Y=7202564107 | en_HK |
dc.identifier.scopusauthorid | Mita, A=36059672600 | en_HK |
dc.identifier.scopusauthorid | Chan, ATC=13404833700 | en_HK |
dc.identifier.citeulike | 6864463 | - |
dc.identifier.issnl | 0006-2952 | - |